EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Structure-Based Virtual Screening for Methyltransferase Inhibitors of SARS-CoV-2 nsp14 and nsp16

Kejue Wu, Yinfeng Guo, Tiefeng Xu, Weifeng Huang iD, Deyin Guo, Liu Cao, Jinping Lei

Molecules · 2024

DOI: 10.3390/molecules29102312 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Kejue Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China. Hauptthemen laut MEDLINE: Viral Nonstructural Proteins, Methyltransferases, SARS-CoV-2, Antiviral Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Key Research and Development Program of China, Guangdong-Hong Kong Technology Cooperation Funding Scheme, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The ongoing COVID-19 pandemic still threatens human health around the world. The methyltransferases (MTases) of SARS-CoV-2, specifically nsp14 and nsp16, play crucial roles in the methylation of the N7 and 2′-O positions of viral RNA, making them promising targets for the development of antiviral drugs. In this work, we performed structure-based virtual screening for nsp14 and nsp16 using the screening workflow (HTVS, SP, XP) of Schrödinger 2019 software, and we carried out biochemical assays and molecular dynamics simulation for the identification of potential MTase inhibitors. For nsp14, we screened 239,000 molecules, leading to the identification of three hits A1–A3 showing N7-MTase inhibition rates greater than 60% under a concentration of 50 µM. For the SAM binding and nsp10-16 interface sites of nsp16, the screening of 210,000 and 237,000 molecules, respectively, from ZINC15 led to the discovery of three hit compounds B1–B3 exhibiting more than 45% of 2′-O-MTase inhibition under 50 µM. These six compounds with moderate MTase inhibitory activities could be used as novel candidates for the further development of anti-SARS-CoV-2 drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Viral Nonstructural ProteinsMethyltransferasesSARS-CoV-2Antiviral AgentsMolecular Dynamics SimulationEnzyme InhibitorsHumansMolecular Docking SimulationDrug Evaluation, PreclinicalCOVID-19 Drug TreatmentCOVID-19Binding SitesExoribonucleases

Stichwörter der Autor:innen

MTase inhibitorsSARS-CoV-2nsp14nsp16structure-based virtual screening

Substanzen

Viral Nonstructural ProteinsMethyltransferasesNSP16 protein, SARS-CoV-2Antiviral AgentsNSP14 protein, SARS-CoV-2Enzyme InhibitorsExoribonucleases

Autor:innen und Institutionen

  • Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
  • Centre for Infection and Immunity Studies (CIIS), School of Medicine, Sun Yat-Sen University, Shenzhen 518107, China.
  • Guangzhou Laboratory, Bio-Island, Guangzhou 510320, China.

ORCID-Profile: Weifeng Huang

Förderung

  • the National Key Research and Development Program of China
  • Guangdong-Hong Kong Technology Cooperation Funding Scheme
  • National Key Research and Development Program of China

Zitieren

APA

Wu, K., Guo, Y., Xu, T., Huang, W., Guo, D., Cao, L., & Lei, J. (2024). Structure-Based Virtual Screening for Methyltransferase Inhibitors of SARS-CoV-2 nsp14 and nsp16. Molecules. https://doi.org/10.3390/molecules29102312

Vancouver

Wu K, Guo Y, Xu T, Huang W, Guo D, Cao L, et al. Structure-Based Virtual Screening for Methyltransferase Inhibitors of SARS-CoV-2 nsp14 and nsp16. Molecules. 2024. doi:10.3390/molecules29102312

BibTeX
@article{Wu2024,
  author = {Wu, Kejue and Guo, Yinfeng and Xu, Tiefeng and Huang, Weifeng and Guo, Deyin and Cao, Liu and Lei, Jinping},
  title = {Structure-Based Virtual Screening for Methyltransferase Inhibitors of SARS-CoV-2 nsp14 and nsp16},
  journal = {Molecules},
  year = {2024},
  doi = {10.3390/molecules29102312}
}
Kostenlos starten →